HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Re: Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial.

AuthorsJ R Benson
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 93 Issue 19 Pg. 1493-4 (Oct 03 2001) ISSN: 0027-8874 [Print] United States
PMID11584068 (Publication Type: Comment, Letter)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
Topics
  • Animals
  • Antineoplastic Agents, Hormonal (administration & dosage, adverse effects, therapeutic use)
  • Breast Neoplasms (drug therapy, epidemiology, pathology)
  • Female
  • Humans
  • Lymph Nodes (pathology)
  • Mice
  • Neoplasms, Second Primary (prevention & control)
  • Randomized Controlled Trials as Topic
  • Selective Estrogen Receptor Modulators (administration & dosage, therapeutic use)
  • Survival Analysis
  • Tamoxifen (administration & dosage, adverse effects, therapeutic use)
  • Time Factors
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: